Recent development in pharmacogenomics: from candidate genes to genome-wide association studies

References

• Cartwright CP. Pharmacogenetics: the Dx perspective. Expert Rev. Mol. Diagn.1(4), 371–376 (2001).
   PubMedGoogle Scholar
• Roses AD. Pharmacogenetics place in modern medical science and practice. Life Sci.70(13), 1471–1480 (2002).
   PubMed Web of Science ®Google Scholar
• Roses AD. Pharmacogenetics and the practice of medicine. Nature405(6788), 857–865 (2000).
   PubMed Web of Science ®Google Scholar
• Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. Pharmacogenomics J.5(3), 149–156 (2005).
   PubMed Web of Science ®Google Scholar
• Stoughton RB, Friend SH. How molecular profiling could revolutionize drug discovery. Nat. Rev. Drug Discov.4(4), 345–350 (2005).
   PubMed Web of Science ®Google Scholar
• Phillips KA, Van Bebber SL. Measuring the value of pharmacogenomics. Nat. Rev. Drug Discov.4(6), 500–509 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med.352(21), 2211–2221 (2005).
   PubMed Web of Science ®Google Scholar
• Voora D, Eby C, Linder MW et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost.93(4), 700–705 (2005).
   PubMed Web of Science ®Google Scholar
• Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther.77(5), 341–352 (2005).
   PubMed Web of Science ®Google Scholar
• de Leon J, Susce MT, Pan RM et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry66(1), 15–27 (2005).
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA279(15), 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Dormann H, Neubert A, Criegee-Rieck M et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J. Int. Med.255(6), 653–663 (2004).
   PubMed Web of Science ®Google Scholar
• Hakonarson H, Thorvaldsson S, Helgadottir A et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA293(18), 2245–2256 (2005).
   PubMed Web of Science ®Google Scholar
• Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull.56(4), 1054–1070 (2000).
   PubMed Web of Science ®Google Scholar
• Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol.41, 815–850 (2001).
   PubMed Web of Science ®Google Scholar
• No authors listed. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur. Respir. J.12(2), 315–335 (1998).
   PubMed Web of Science ®Google Scholar
• Eder W, Ege MJ, von Mutius E. The asthma epidemic. N. Engl. J. Med.355(21), 2226–2235 (2006).
   PubMed Web of Science ®Google Scholar
• Van Eerdewegh P, Little RD, Dupuis J et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature418(6896), 426–430 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Leaves NI, Anderson GG et al. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat. Genet.34(2), 181–186 (2003).
   PubMed Web of Science ®Google Scholar
• Laitinen T, Polvi A, Rydman P et al. Characterization of a common susceptibility locus for asthma-related traits. Science304(5668), 300–304 (2004).
   PubMed Web of Science ®Google Scholar
• Hakonarson H, Gulcher JR, Stefansson K. deCODE genetics, Inc. Pharmacogenomics4(2), 209–215 (2003).
   PubMed Web of Science ®Google Scholar
• McLeod HL. Pharmacogenetics: more than skin deep. Nat. Genet.29(3), 247–248 (2001).
   PubMed Web of Science ®Google Scholar
• Fenech A, Hall IP. Pharmacogenetics of asthma. Br. J. Clin. Pharmacol.53(1), 3–15 (2002).
   PubMed Web of Science ®Google Scholar
• Hall IP. Pharmacogenetics, pharmacogenomics and airway disease. Respir. Res.3, 10 (2002).
   PubMedGoogle Scholar
• Roses AD. Pharmacogenetics and future drug development and delivery. Lancet355(9212), 1358–1361 (2000).
   PubMed Web of Science ®Google Scholar
• Hakonarson H, Wjst M. Current concepts on the genetics of asthma. Curr. Opin. Pediatr.13(3), 267–277 (2001).
   PubMed Web of Science ®Google Scholar
• Bateman ED. Measuring asthma control. Curr. Opin. Allergy Clin. Immunol.1(3), 211–216 (2001).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med.170(8), 836–844 (2004).
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Martin RJ, King TS et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol.109(3), 410–418 (2002).
   PubMed Web of Science ®Google Scholar
• Ledford D, Apter A, Brenner AM et al. Osteoporosis in the corticosteroid-treated patient with asthma. J. Allergy Clin. Immunol.102(3), 353–362 (1998).
   PubMed Web of Science ®Google Scholar
• Wong CA, Walsh LJ, Smith CJ et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet355(9213), 1399–1403 (2000).
   PubMed Web of Science ®Google Scholar
• Baylink DJ. Glucocorticoid-induced osteoporosis. N. Engl. J. Med.309(5), 306–308 (1983).
   PubMed Web of Science ®Google Scholar
• Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA277(9), 722–727 (1997).
   PubMed Web of Science ®Google Scholar
• Garbe E, Boivin JF, LeLorier J, Suissa S. Selection of controls in database case–control studies: glucocorticoids and the risk of glaucoma. J. Clin. Epidemiol.51(2), 129–135 (1998).
   PubMed Web of Science ®Google Scholar
• Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N. Engl. J. Med.337(1), 8–14 (1997).
   PubMed Web of Science ®Google Scholar
• Chinchilli VM. General principles for systematic reviews and meta-analyses and a critique of a recent systematic review of long-acting β-agonists. J. Allergy Clin. Immunol.119(2), 303–306 (2007).
   PubMed Web of Science ®Google Scholar
• Choudhry S, Ung N, Avila PC et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am. J. Respir. Crit. Care Med.171(6), 563–570 (2005).
   PubMed Web of Science ®Google Scholar
• Litonjua AA, Silverman EK, Tantisira KG et al. β2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest126(1), 66–74 (2004).
   PubMed Web of Science ®Google Scholar
• Chalmers GW, Macleod KJ, Little SA et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax57(3), 226–230 (2002).
   PubMed Web of Science ®Google Scholar
• Palmer LJ, Cookson WO. Using single nucleotide polymorphisms as a means to understanding the pathophysiology of asthma. Respir. Res.2(2), 102–112 (2001).
   PubMed Web of Science ®Google Scholar
• Gray IC, Campbell DA, Spurr NK. Single nucleotide polymorphisms as tools in human genetics. Hum. Mol. Genet.9(16), 2403–2408 (2000).
   PubMed Web of Science ®Google Scholar
• Schork NJ, Fallin D, Lanchbury JS. Single nucleotide polymorphisms and the future of genetic epidemiology. Clin. Genet.58(4), 250–264 (2000).
   PubMed Web of Science ®Google Scholar
• Sears MR. Asthma treatment: inhaled β-agonists. Can. Respir. J.5(Suppl. A), 54A–59A (1998).
   PubMedGoogle Scholar
• Hancox RJ, Sears MR, Taylor DR. Polymorphism of the β2-adrenoceptor and the response to long-term β2-agonist therapy in asthma. Eur. Respir. J.11(3), 589–593 (1998).
   PubMed Web of Science ®Google Scholar
• Billington CK, Penn RB. Signaling and regulation of G protein-coupled receptors in airway smooth muscle. Respir. Res.4, 2 (2003).
   PubMed Web of Science ®Google Scholar
• Drysdale CM, McGraw DW, Stack CB et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA97(19), 10483–10488 (2000).
   PubMed Web of Science ®Google Scholar
• Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol.8(3), 334–339 (1993).
   PubMed Web of Science ®Google Scholar
• Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest.100(12), 3184–3188 (1997).
   PubMed Web of Science ®Google Scholar
• Kotani Y, Nishimura Y, Maeda H, Yokoyama M. β2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J. Asthma36(7), 583–590 (1999).
   PubMed Web of Science ®Google Scholar
• Lima JJ, Thomason DB, Mohamed MH et al. Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther.65(5), 519–525 (1999).
   PubMed Web of Science ®Google Scholar
• Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet350(9083), 995–999 (1997).
   PubMed Web of Science ®Google Scholar
• Cho SH, Oh SY, Bahn JW et al. Association between bronchodilating response to short-acting β-agonist and non-synonymous single-nucleotide polymorphisms of β-adrenoceptor gene. Clin. Exp. Allergy35(9), 1162–1167 (2005).
   PubMed Web of Science ®Google Scholar
• Kukreti R, Bhatnagar P, B-Rao C et al. β2-adrenergic receptor polymorphisms and response to salbutamol among Indian asthmatics*. Pharmacogenomics6(4), 399–410 (2005).
   PubMed Web of Science ®Google Scholar
• Israel E. Assessment of therapeutic index of inhaled steroids. Lancet356(9229), 527–528 (2000).
   PubMed Web of Science ®Google Scholar
• Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet364(9444), 1505–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Jackson CM, Lipworth B. Benefit–risk assessment of long-acting β2-agonists in asthma. Drug Saf.27(4), 243–270 (2004).
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Walters J, Walters EH. Adverse effects of β-agonists: are they clinically relevant? Am. J. Respir. Med.2(4), 287–297 (2003).
   PubMedGoogle Scholar
• Tsai HJ, Shaikh N, Kho JY et al. β2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum. Genet.119(5), 547–557 (2006).
   PubMed Web of Science ®Google Scholar
• Snyder EM, Beck KC, Dietz NM et al. Influence of β2-adrenergic receptor genotype on airway function during exercise in healthy adults. Chest129(3), 762–770 (2006).
   PubMed Web of Science ®Google Scholar
• Silverman EK, Kwiatkowski DJ, Sylvia JS et al. Family-based association analysis of β2-adrenergic receptor polymorphisms in the childhood asthma management program. J. Allergy Clin. Immunol.112(5), 870–876 (2003).
   PubMed Web of Science ®Google Scholar
• Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos. Trans. R. Soc. Lond. B Biol. Sci.360(1460), 1617–1638 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein DB. The genetics of human drug response. Philos. Trans. R. Soc. Lond. B Biol. Sci.360(1460), 1571–1572 (2005).
   PubMed Web of Science ®Google Scholar
• Silverman ES, Du J, De Sanctis GT et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am. J. Respir. Cell Mol. Biol.19(2), 316–323 (1998).
   PubMed Web of Science ®Google Scholar
• Drazen JM, Silverman ES. Genetic determinants of 5-lipoxygenase transcription. Int. Arch. Allergy Immunol.118(2–4), 275–278 (1999).
   PubMed Web of Science ®Google Scholar
• Sampson AP, Cowburn AS, Sladek K et al. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int. Arch. Allergy Immunol.113(1–3), 355–357 (1997).
   PubMed Web of Science ®Google Scholar
• Sampson AP, Siddiqui S, Buchanan D et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax55(Suppl. 2), S28–S31 (2000).
   PubMed Web of Science ®Google Scholar
• Currie GP, Lima JJ, Sylvester JE et al. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br. J. Clin. Pharmacol.56(4), 422–426 (2003).
   PubMed Web of Science ®Google Scholar
• Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet350(9091), 1599–1600 (1997).
   PubMed Web of Science ®Google Scholar
• Deykin A, Wechsler ME, Boushey HA et al. Combination therapy with a long-acting β-agonist and a leukotriene antagonist in moderate asthma. Am. J. Respir. Crit. Care Med.175(3), 228–234 (2007).
   PubMed Web of Science ®Google Scholar
• Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am. J. Respir. Crit. Care Med.175(3), 235–242 (2007).
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Lee T, Kemp JP et al. Safety and clinical efficacy of zileuton in patients with chronic asthma. Am. J. Manag. Care4(6), 841–848 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J. Allergy Clin. Immunol.102(4 Pt 1), 531–538 (1998).
   PubMed Web of Science ®Google Scholar
• Gagliardo R, Chanez P, Vignola AM et al. Glucocorticoid receptor α and β in glucocorticoid dependent asthma. Am. J. Respir. Crit. Care Med.162(1), 7–13 (2000).
   PubMed Web of Science ®Google Scholar
• Sher ER, Leung DY, Surs W et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J. Clin. Invest.93(1), 33–39 (1994).
   PubMed Web of Science ®Google Scholar
• Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J. Allergy Clin. Immunol.101(5), 594–601 (1998).
   PubMed Web of Science ®Google Scholar
• Chikanza LC, Panayi GS. The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin-2 and -4 production in corticosteroid sensitive and resistant subjects. Eur. J. Clin. Invest.23(12), 845–850 (1993).
   PubMed Web of Science ®Google Scholar
• Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor β-isoform. J. Allergy Clin. Immunol.105(5), 943–950 (2000).
   PubMed Web of Science ®Google Scholar
• Lane SJ, Lee TH. Mechanisms of corticosteroid resistance in asthmatic patients. Int. Arch. Allergy Immunol.113(1–3), 193–195 (1997).
   PubMed Web of Science ®Google Scholar
• Leung DY, Chrousos GP. Is there a role for glucocorticoid receptor β in glucocorticoid-dependent asthmatics? Am. J. Respir. Crit. Care Med.162(1), 1–3 (2000).
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet.13(13), 1353–1359 (2004).
   PubMed Web of Science ®Google Scholar
• Hakonarson H, Bjornsdottir US, Halapi E et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc. Natl Acad. Sci. USA102(41), 14789–14794 (2005).
   PubMed Web of Science ®Google Scholar
• Hakonarson H, Halapi E, Whelan R et al. Association between IL-1β/TNF-α-induced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle. Am. J. Respir. Cell Mol. Biol.25(6), 761–771 (2001).
   PubMed Web of Science ®Google Scholar
• Kim MH, Agrawal DK. Effect of interleukin-1β and tumor necrosis factor-α on the expression of G-proteins in CD4+ T-cells of atopic asthmatic subjects. J. Asthma39(5), 441–448 (2002).
   PubMed Web of Science ®Google Scholar
• Roth M, Black JL. Transcription factors in asthma: are transcription factors a new target for asthma therapy? Curr. Drug Targets7(5), 589–595 (2006).
   PubMed Web of Science ®Google Scholar
• D’Acquisto F, Ianaro A. From willow bark to peptides: the ever widening spectrum of NF-κB inhibitors. Curr. Opin. Pharmacol.6(4), 387–392 (2006).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Pierik M, Hlavaty T et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn’s disease but not with susceptibility to IBD. Gastroenterology129(6), 1845–1853 (2005).
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature411(6837), 599–603 (2001).
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature411(6837), 603–606 (2001).
   PubMed Web of Science ®Google Scholar
• Rioux JD, Daly MJ, Silverberg MS et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet.29(2), 223–228 (2001).
   PubMed Web of Science ®Google Scholar
• Peltekova VD, Wintle RF, Rubin LA et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet.36(5), 471–475 (2004).
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science314(5804), 1461–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Hue S, Ahern P, Buonocore S et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med.203(11), 2473–2483 (2006).
   PubMed Web of Science ®Google Scholar
• Kullberg MC, Jankovic D, Feng CG et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med.203(11), 2485–2494 (2006).
   PubMed Web of Science ®Google Scholar
• Baldassano RN, Bradfield JP, Monos DS et al. Association of variants of the interleukin-23 receptor (IL23R) gene with susceptibility to pediatric Crohn’s disease. Clin. Gastroenterol. Hepatol. (2007) (In Press).
   Google Scholar
• Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity13(5), 715–725 (2000).
   PubMed Web of Science ®Google Scholar
• Becker C, Wirtz S, Blessing M et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest.112(5), 693–706 (2003).
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet.39(2), 207–211 (2007).
   PubMed Web of Science ®Google Scholar
• Patterson M, Cardon L. Replication publication. PLoS Biol.3(9), e327 (2005).
   PubMedGoogle Scholar
• Baldassano RN, Bradfield JP, Monos DS et al. Association of the T300A non-synonymous variant of the ATG16L1 gene with susceptibility to pediatric Crohn’s disease. Gut (2007) (In Press).
   PubMedGoogle Scholar
• Helgadottir A, Manolescu A, Thorleifsson G et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet.36(3), 233–239 (2004).
   PubMed Web of Science ®Google Scholar
• Ford-Hutchinson AW. Leukotriene B4 in inflammation. Crit. Rev. Immunol.10(1), 1–12 (1990).
   PubMed Web of Science ®Google Scholar
• Dahlen B, Kumlin M, Ihre E, Zetterstrom O, Dahlen SE. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax52(4), 342–347 (1997).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med.347(20), 1557–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation108(3), 250–252 (2003).
   PubMedGoogle Scholar
• Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107(3), 499–511 (2003).
   PubMed Web of Science ®Google Scholar
• Malik I, Danesh J, Whincup P et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet358(9286), 971–976 (2001).
   PubMed Web of Science ®Google Scholar
• Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis3(4), 57–68 (2002).
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Manolescu A, Helgason A et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet.38(1), 68–74 (2006).
   PubMed Web of Science ®Google Scholar
• Bamshad M, Wooding S, Salisbury BA, Stephens JC. Deconstructing the relationship between genetics and race. Nat. Rev. Genet.5(8), 598–609 (2004).
   PubMed Web of Science ®Google Scholar
• Jorde LB, Wooding SP. Genetic variation, classification and ‘race’. Nat. Genet.36(11 Suppl.), S28–S33 (2004).
   PubMed Web of Science ®Google Scholar
• Royal CD, Dunston GM. Changing the paradigm from ‘race’ to human genome variation. Nat. Genet.36(11 Suppl.), S5–S7 (2004).
   PubMed Web of Science ®Google Scholar
• Maitland-van der Zee AH, Turner ST, Schwartz GL et al. A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet. Genomics15(5), 287–293 (2005).
   PubMed Web of Science ®Google Scholar
• McNamara DM. Pharmacogenetics in heart failure: genomic markers of endothelial and neurohumoral function. Congest. Heart Fail.10(6), 302–308 (2004).
   PubMedGoogle Scholar
• Liljedahl U, Kahan T, Malmqvist K et al. Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. J. Hypertens.22(12), 2321–2328 (2004).
   PubMed Web of Science ®Google Scholar
• Vadlamani L, Iyengar S. Tumor necrosis factor α polymorphism in heart failure/cardiomyopathy. Congest. Heart Fail.10(6), 289–292 (2004).
   PubMedGoogle Scholar
• Mellen PB, Herrington DM. Pharmacogenomics of blood pressure response to antihypertensive treatment. J. Hypertens.23(7), 1311–1325 (2005).
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature414(6865), 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β-catenin and glycogen synthase kinase-3β. J. Biol. Chem.280(2), 1457–1464 (2005).
   PubMed Web of Science ®Google Scholar
• Rich SS. Mapping genes in diabetes. Genetic epidemiological perspective. Diabetes39(11), 1315–1319 (1990).
   PubMed Web of Science ®Google Scholar
• Tattersall RB. Mild familial diabetes with dominant inheritance. Q J. Med.43(170), 339–357 (1974).
   PubMedGoogle Scholar
• Tattersal RB, Fajans SS. Prevalence of diabetes and glucose intolerance in 199 offspring of thirty-seven conjugal diabetic parents. Diabetes24(5), 452–462 (1975).
   PubMed Web of Science ®Google Scholar
• Froguel P, Zouali H, Vionnet N et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N. Engl. J. Med.328(10), 697–702 (1993).
   PubMed Web of Science ®Google Scholar
• Frayling TM, Bulamn MP, Ellard S et al. Mutations in the hepatocyte nuclear factor-1α gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes46(4), 720–725 (1997).
   PubMed Web of Science ®Google Scholar
• Hattersley AT, Beards F, Ballantyne E et al. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat. Genet.19(3), 268–270 (1998).
   PubMed Web of Science ®Google Scholar
• Grimsby J, Sarabu R, Corbett WL et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science301(5631), 370–373 (2003).
   PubMed Web of Science ®Google Scholar
• Matschinsky FM, Magnuson MA, Zelent D et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes55(1), 1–12 (2006).
   PubMed Web of Science ®Google Scholar
• Hattersley AT, Turner RC, Permutt MA et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet339(8805), 1307–1310 (1992).
   PubMed Web of Science ®Google Scholar
• Njolstad PR, Sovik O, Cuesta-Munoz A et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl. J. Med.344(21), 1588–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Heiervang E, Folling I, Sovik O et al. Maturity-onset diabetes of the young. Studies in a Norwegian family. Acta Paediatr. Scand.78(1), 74–80 (1989).
   PubMed Web of Science ®Google Scholar
• Sovik O, Njolstad P, Folling I et al. Hyperexcitability to sulphonylurea in MODY3. Diabetologia41(5), 607–608 (1998).
   PubMed Web of Science ®Google Scholar
• Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1α gene mutations: evidence for pharmacogenetics in diabetes. Diabet. Med.17(7), 543–545 (2000).
   PubMed Web of Science ®Google Scholar
• Shepherd M, Pearson ER, Houghton J et al. No deterioration in glycemic control in HNF-1α maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care26(11), 3191–3192 (2003).
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Pearson ER, Antcliff JF et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med.350(18), 1838–1849 (2004).
   PubMed Web of Science ®Google Scholar
• Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care28(3), 758–759 (2005).
   PubMed Web of Science ®Google Scholar
• Klupa T, Edghill EL, Nazim J et al. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of β cell function among carriers of the R201H mutation. Diabetologia48(5), 1029–1031 (2005).
   PubMed Web of Science ®Google Scholar
• Sagen JV, Raeder H, Hathout E et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes53(10), 2713–2718 (2004).
   PubMed Web of Science ®Google Scholar
• Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J. Clin. Endocrinol. Metab.89(11), 5504–5507 (2004).
   PubMed Web of Science ®Google Scholar
• Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of Type 2 diabetes. Nat. Genet.26(1), 76–80 (2000).
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with Type 2 diabetes. Diabetes52(2), 568–572 (2003).
   PubMed Web of Science ®Google Scholar
• Florez JC, Burtt N, de Bakker PI et al. Haplotype structure and genotype–phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes53(5), 1360–1368 (2004).
   PubMed Web of Science ®Google Scholar
• Sladek R, Rocheleau G, Rung J et al. A genome-wide association study identifies novel risk loci for Type 2 diabetes. Nature445(7130), 881–885 (2007).
   PubMed Web of Science ®Google Scholar
• Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet.38(3), 320–323 (2006).
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, Bayley N et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med.355(3), 241–250 (2006).
   PubMed Web of Science ®Google Scholar
• Damcott CM, Pollin TI, Reinhart LJ et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with Type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes55(9), 2654–2659 (2006).
   PubMed Web of Science ®Google Scholar
• Groves CJ, Zeggini E, Minton J et al. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a Type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes55(9), 2640–2644 (2006).
   PubMed Web of Science ®Google Scholar
• Scott LJ, Bonnycastle LL, Willer CJ et al. Association of transcription factor 7-like 2 (TCF7L2) variants with Type 2 diabetes in a Finnish sample. Diabetes55(9), 2649–2653 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang C, Qi L, Hunter DJ et al. Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of Type 2 diabetes in large cohorts of U.S. women and men. Diabetes55(9), 2645–2648 (2006).
   PubMed Web of Science ®Google Scholar
• Cauchi S, Meyre D, Dina C et al. Transcription factor TCF7L2 genetic study in the French population: expression in human β-cells and adipose tissue and strong association with Type 2 diabetes. Diabetes55(10), 2903–2908 (2006).
   PubMed Web of Science ®Google Scholar
• Saxena R, Gianniny L, Burtt NP et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with Type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes55(10), 2890–2895 (2006).
   PubMed Web of Science ®Google Scholar
• Chandak GR, Janipalli CS, Bhaskar S et al. Common variants in the TCF7L2 gene are strongly associated with Type 2 diabetes mellitus in the Indian population. Diabetologia50(1), 63–67 (2007).
   PubMed Web of Science ®Google Scholar
• Humphries SE, Gable D, Cooper JA et al. Common variants in the TCF7L2 gene and predisposition to Type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women. J. Mol. Med.84(12), 1–10 (2006).
   PubMed Web of Science ®Google Scholar
• van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A et al. Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to Type 2 diabetes in the Dutch Breda cohort. Diabetologia50(1), 59–62 (2007).
   PubMed Web of Science ®Google Scholar
• Helgason A, Palsson S, Thorleifsson G et al. Refining the impact of TCF7L2 gene variants on Type 2 diabetes and adaptive evolution. Nat. Genet.39(2), 218–225 (2007).
   PubMed Web of Science ®Google Scholar
• Bennett RG, Hamel FG, Duckworth WC. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes52(9), 2315–2320 (2003).
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo.Proc. Natl Acad. Sci. USA100(7), 4162–4167 (2003).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med.335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA279(20), 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333(20), 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am. J. Hum. Genet.33(1), 11–24 (1981).
   PubMed Web of Science ®Google Scholar
• Ordovas JM, Lopez-Miranda J, Perez-Jimenez F et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis113(2), 157–166 (1995).
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med.338(2), 86–93 (1998).
   PubMed Web of Science ®Google Scholar
• de Maat MP, Kastelein JJ, Jukema JW et al. -455G/A polymorphism of the β-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler. Thromb. Vasc. Biol.18(2), 265–271 (1998).
   PubMed Web of Science ®Google Scholar
• Jukema JW, van Boven AJ, Groenemeijer B et al. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Circulation94(8), 1913–1918 (1996).
   PubMedGoogle Scholar
• Poirier J, Minnich A, Davignon J. Apolipoprotein E, synaptic plasticity and Alzheimer’s disease. Ann. Med.27(6), 663–670 (1995).
   PubMed Web of Science ®Google Scholar
• Richard F, Helbecque N, Neuman E et al. APOE genotyping and response to drug treatment in Alzheimer’s disease. Lancet349(9051), 539 (1997).
   PubMed Web of Science ®Google Scholar
• Rennert NJ, Charney P. Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care. Prim. Care30(3), 569–592 (2003).
   PubMed Web of Science ®Google Scholar
• Dominiczak MH. Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. Clin. Chem. Lab. Med.41(9), 1266–1278 (2003).
   PubMed Web of Science ®Google Scholar
• Hauner H, Meier M, Jockel KH, Frey UH, Siffert W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein β3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics13(8), 453–459 (2003).
   PubMedGoogle Scholar
• Friedman JM. Modern science versus the stigma of obesity. Nat. Med.10(6), 563–569 (2004).
   PubMed Web of Science ®Google Scholar
• Lyon HN, Hirschhorn JN. Genetics of common forms of obesity: a brief overview. Am. J. Clin. Nutr.82(1 Suppl.), 215S–217S (2005).
   PubMed Web of Science ®Google Scholar
• Knowler WC, Pettitt DJ, Saad MF, Bennett PH. Diabetes mellitus in the Pima Indians: incidence, risk factors and pathogenesis. Diabetes Metab. Rev.6(1), 1–27 (1990).
   PubMed Web of Science ®Google Scholar
• Zimmet P, Dowse G, Finch C, Serjeantson S, King H. The epidemiology and natural history of NIDDM – lessons from the South Pacific. Diabetes Metab. Rev.6(2), 91–124 (1990).
   PubMed Web of Science ®Google Scholar
• Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. JAMA256(1), 51–54 (1986).
   PubMed Web of Science ®Google Scholar
• Borjeson M. The aetiology of obesity in children. A study of 101 twin pairs. Acta Paediatr. Scand.65(3), 279–287 (1976).
   PubMed Web of Science ®Google Scholar
• Hebebrand J, Friedel S, Schauble N, Geller F, Hinney A. Perspectives: molecular genetic research in human obesity. Obes. Rev.4(3), 139–146 (2003).
   PubMedGoogle Scholar
• Farooqi IS, O’Rahilly S. New advances in the genetics of early onset obesity. Int. J. Obes.29(10), 1149–1152 (2005).
   PubMed Web of Science ®Google Scholar
• Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat. Rev. Genet.6(3), 221–234 (2005).
   PubMed Web of Science ®Google Scholar
• Schousboe K, Willemsen G, Kyvik KO et al. Sex differences in heritability of BMI: a comparative study of results from twin studies in eight countries. Twin Res.6(5), 409–421 (2003).
   PubMedGoogle Scholar
• Herbert A, Gerry NP, McQueen MB et al. A common genetic variant is associated with adult and childhood obesity. Science312(5771), 279–283 (2006).
   PubMed Web of Science ®Google Scholar
• Loos RJ, Barroso I, O’Rahilly S, Wareham NJ. Comment on “A common genetic variant is associated with adult and childhood obesity”. Science315(5809), 187; author reply 187 (2007).
   PubMedGoogle Scholar
• Dina C, Meyre D, Samson C et al. Comment on “A common genetic variant is associated with adult and childhood obesity”. Science315(5809), 187; author reply 187 (2007).
   PubMedGoogle Scholar
• Rosskopf D, Bornhorst A, Rimmbach C et al. Comment on “A common genetic variant is associated with adult and childhood obesity”. Science315(5809), 187; author reply 187 (2007).
   PubMedGoogle Scholar
• Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science316(5826), 889–894 (2007).
   PubMed Web of Science ®Google Scholar
• Riggs BL, Melton LJ III. Involutional osteoporosis. N. Engl. J. Med.314(26), 1676–1686 (1986).
   PubMed Web of Science ®Google Scholar
• Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J. Bone Miner. Res.7(9), 1005–1010 (1992).
   PubMed Web of Science ®Google Scholar
• Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res.12(1), 24–35 (1997).
   PubMed Web of Science ®Google Scholar
• Hollingworth W, Todd CJ, Parker MJ. The cost of treating hip fractures in the twenty-first century. J. Public Health Med.17(3), 269–276 (1995).
   PubMedGoogle Scholar
• Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos. Int.2(6), 285–289 (1992).
   PubMed Web of Science ®Google Scholar
• Heaney RP, Abrams S, Dawson-Hughes B et al. Peak bone mass. Osteoporos. Int.11(12), 985–1009 (2000).
   PubMed Web of Science ®Google Scholar
• Mora S, Gilsanz V. Establishment of peak bone mass. Endocrinol. Metab. Clin. North Am.32(1), 39–63 (2003).
   PubMed Web of Science ®Google Scholar
• Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral density. J. Bone Miner. Res.8(1), 1–9 (1993).
   PubMed Web of Science ®Google Scholar
• Gueguen R, Jouanny P, Guillemin F et al. Segregation analysis and variance components analysis of bone mineral density in healthy families. J. Bone Miner. Res.10(12), 2017–2022 (1995).
   PubMed Web of Science ®Google Scholar
• Seeman E, Hopper JL, Bach LA et al. Reduced bone mass in daughters of women with osteoporosis. N. Engl. J. Med.320(9), 554–558 (1989).
   PubMed Web of Science ®Google Scholar
• Soroko SB, Barrett-Connor E, Edelstein SL, Kritz-Silverstein D. Family history of osteoporosis and bone mineral density at the axial skeleton: the Rancho Bernardo Study. J. Bone Miner. Res.9(6), 761–769 (1994).
   PubMed Web of Science ®Google Scholar
• Morrison NA, Qi JC, Tokita A et al. Prediction of bone density from vitamin D receptor alleles. Nature367(6460), 284–287 (1994).
   PubMed Web of Science ®Google Scholar
• Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J. Bone Miner. Res.11(12), 1841–1849 (1996).
   PubMed Web of Science ®Google Scholar
• Sainz J, Van Tornout JM, Loro ML et al. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N. Engl. J. Med.337(2), 77–82 (1997).
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Rizzoli R, Slosman DO, Bonjour JP. Do dietary calcium and age explain the controversy surrounding the relationship between bone mineral density and vitamin D receptor gene polymorphisms? J. Bone Miner. Res.13(3), 363–370 (1998).
   PubMed Web of Science ®Google Scholar
• Matsuyama T, Ishii S, Tokita A et al. Vitamin D receptor genotypes and bone mineral density. Lancet345(8959), 1238–1239 (1995).
   PubMed Web of Science ®Google Scholar
• Hunter D, Major P, Arden N et al. A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. J. Bone Miner. Res.15(11), 2276–2283 (2000).
   PubMed Web of Science ®Google Scholar
• Howard G, Nguyen T, Morrison N et al. Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J. Clin. Endocrinol. Metab.80(9), 2800–2805 (1995).
   PubMed Web of Science ®Google Scholar
• Massart F, Reginster JY, Brandi ML. Genetics of menopause-associated diseases. Maturitas40(2), 103–116 (2001).
   PubMed Web of Science ®Google Scholar
• Gennari L, Becherini L, Falchetti A et al. Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. J. Steroid. Biochem. Mol. Biol.81(1), 1–24 (2002).
   PubMed Web of Science ®Google Scholar
• Han KO, Moon IG, Kang YS et al. Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J. Clin. Endocrinol. Metab.82(4), 991–995 (1997).
   PubMed Web of Science ®Google Scholar
• Deng HW, Li J, Li JL et al. Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum. Genet.103(5), 576–585 (1998).
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Fujino T, Shirogane T et al. Estrogen receptor α polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas41(3), 193–201 (2002).
   PubMed Web of Science ®Google Scholar
• Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P et al. Oestrogen-receptor-α gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin. Endocrinol.52(5), 581–585 (2000).
   PubMed Web of Science ®Google Scholar
• Kinuta K, Tanaka H, Moriwake Tet al. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology141(4), 1317–1324 (2000).
   PubMed Web of Science ®Google Scholar
• Salmen T, Heikkinen AM, Mahonen A et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J. Bone Miner. Res.15(2), 315–321 (2000).
   PubMed Web of Science ®Google Scholar
• Salmen T, Heikkinen AM, Mahonen A et al. The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor α genotype in early postmenopausal women. J. Bone Miner. Res.15(12), 2479–2486 (2000).
   PubMed Web of Science ®Google Scholar
• Grant SF, Reid DM, Blake G et al. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen Type I α1 gene. Nat. Genet.14(2), 203–205 (1996).
   PubMed Web of Science ®Google Scholar
• Uitterlinden AG, Burger H, Huang Q et al. Relation of alleles of the collagen Type Iα1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N. Engl. J. Med.338(15), 1016–1021 (1998).
   PubMed Web of Science ®Google Scholar
• Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet.33(2), 177–182 (2003).
   PubMed Web of Science ®Google Scholar
• Mann V, Hobson EE, Li B et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J. Clin. Invest.107(7), 899–907 (2001).
   PubMed Web of Science ®Google Scholar
• Qureshi AM, Herd RJ, Blake GM, Fogelman I, Ralston SH. COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif. Tissue Int.70(3), 158–163 (2002).
   PubMed Web of Science ®Google Scholar
• Little RD, Carulli JP, Del Mastro RG et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet.70(1), 11–19 (2002).
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med.346(20), 1513–1521 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson ML, Gong G, Kimberling W et al. Linkage of a gene causing high bone mass to human chromosome 11 (11q12–13). Am. J. Hum. Genet.60(6), 1326–1332 (1997).
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell107(4), 513–523 (2001).
   PubMed Web of Science ®Google Scholar
• Wang L, Nguyen TV, McLaughlin RW et al. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl Acad. Sci. USA102(26), 9394–9399 (2005).
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA293(12), 1485–1489 (2005).
   PubMed Web of Science ®Google Scholar
• Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol.20(8), 1149–1157 (2005).
   PubMed Web of Science ®Google Scholar
• McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia14(4), 567–572 (2000).
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Fischer C, Brockmeier D et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics14(7), 407–417 (2004).
   PubMedGoogle Scholar
• Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics14(12), 785–792 (2004).
   PubMedGoogle Scholar
• Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev.26(1), 183–201 (2007).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235(4785), 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244(4905), 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin. Cancer Biol.4(1), 19–26 (1993).
   PubMed Web of Science ®Google Scholar
• Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta1198(2–3), 165–184 (1994).
   PubMed Web of Science ®Google Scholar
• Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist3(4), 237–252 (1998).
   PubMedGoogle Scholar
• Bast RC Jr, Ravdin P, Hayes DF et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol.19(6), 1865–1878 (2001).
   PubMed Web of Science ®Google Scholar
• Savage DG, Antman KH. Imatinib mesylate – a new oral targeted therapy. N. Engl. J. Med.346(9), 683–693 (2002).
   PubMed Web of Science ®Google Scholar
• Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell1(2), 117–123 (2002).
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr–abl fused gene. Cell47(2), 277–284 (1986).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Vandel P, Talon JM, Haffen E, Sechter D. Pharmacogenetics and drug therapy in psychiatry – the role of the CYP2D6 polymorphism. Curr. Pharm. Des.13(2), 241–250 (2007).
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Brett CM, Altman RB et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther.81(3), 328–345 (2007).
   PubMed Web of Science ®Google Scholar
• Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug. Metab. Rev.37(2), 327–378 (2005).
   PubMed Web of Science ®Google Scholar
• Szekeres T, Haushofer A. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics6(2), 163–168 (2005).
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhang Y, Wang Y et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab. Dispos.33(6), 749–753 (2005).
   PubMed Web of Science ®Google Scholar
• Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav.7(1), 18–36 (2005).
   PubMed Web of Science ®Google Scholar
• Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA102(15), 5507–5512 (2005).
   PubMed Web of Science ®Google Scholar
• Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA293(5), 596–608 (2005).
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol.29(6), 1021–1028 (2005).
   Google Scholar
• Wilffert B, Zaal R, Brouwers JR. Pharmacogenetics as a tool in the therapy of schizophrenia. Pharm. World. Sci.27(1), 20–30 (2005).
   PubMedGoogle Scholar
• Lepper ER, Nooter K, Verweij J et al. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics6(2), 115–138 (2005).
   PubMed Web of Science ®Google Scholar
• Hulot JS, Villard E, Maguy A et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet. Genomics15(5), 277–285 (2005).
   PubMed Web of Science ®Google Scholar
• Carlborg O, Haley CS. Epistasis: too often neglected in complex trait studies? Nat. Rev. Genet.5(8), 618–625 (2004).
   PubMed Web of Science ®Google Scholar
• Marchini J, Donnelly P, Cardon LR. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat. Genet.37(4), 413–417 (2005).
   PubMed Web of Science ®Google Scholar
• Nagel RL. Epistasis and the genetics of human diseases. C. R. Biol.328(7), 606–615 (2005).
   PubMed Web of Science ®Google Scholar
• Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum. Hered.56(1–3), 73–82 (2003).
   PubMed Web of Science ®Google Scholar
• Ober C. Perspectives on the past decade of asthma genetics. J. Allergy Clin. Immunol.116(2), 274–278 (2005).
   PubMed Web of Science ®Google Scholar
• Zambelli-Weiner A, Ehrlich E, Stockton ML et al. Evaluation of the CD14/-260 polymorphism and house dust endotoxin exposure in the Barbados Asthma Genetics Study. J. Allergy Clin. Immunol.115(6), 1203–1209 (2005).
   PubMed Web of Science ®Google Scholar
• Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene–gene and gene–environment interactions. Bioinformatics19(3), 376–382 (2003).
   PubMed Web of Science ®Google Scholar
• Palmer LJ, Cardon LR. Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet366(9492), 1223–1234 (2005).
   PubMed Web of Science ®Google Scholar
• Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet366(9493), 1315–1323 (2005).
   PubMed Web of Science ®Google Scholar
• Cardon LR, Bell JI. Association study designs for complex diseases. Nat. Rev. Genet.2(2), 91–99 (2001).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Genetic associations: false or true? Trends Mol. Med.9(4), 135–138 (2003).
   PubMed Web of Science ®Google Scholar
• Glazier AM, Nadeau JH, Aitman TJ. Finding genes that underlie complex traits. Science298(5602), 2345–2349 (2002).
   PubMed Web of Science ®Google Scholar
• Page GP, George V, Go RC, Page PZ, Allison DB. “Are we there yet?”: deciding when one has demonstrated specific genetic causation in complex diseases and quantitative traits. Am. J. Hum. Genet.73(4), 711–719 (2003).
   PubMed Web of Science ®Google Scholar
• Cordell HJ, Clayton DG. Genetic association studies. Lancet366(9491), 1121–1131 (2005).
   PubMed Web of Science ®Google Scholar
• Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet.6(2), 95–108 (2005).
   PubMed Web of Science ®Google Scholar
• Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat. Rev. Genet.6(2), 109–118 (2005).
   PubMed Web of Science ®Google Scholar
• Syvanen AC. Toward genome-wide SNP genotyping. Nat. Genet.37(Suppl.), S5–S10 (2005).
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science308(5720), 385–389 (2005).
   PubMed Web of Science ®Google Scholar